Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos announces full year 2023 results and outlook for 2024
04:01pm, Thursday, 22'nd Feb 2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023
Galapagos presents at EBMT-EHA annual meeting 2024
04:01pm, Thursday, 15'th Feb 2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
04:01pm, Wednesday, 31'st Jan 2024
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to A
Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (N
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
04:01pm, Wednesday, 03'rd Jan 2024
Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Bioscience
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
04:01pm, Wednesday, 03'rd Jan 2024
BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
01:00am, Tuesday, 02'nd Jan 2024
Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgoti
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
04:01pm, Tuesday, 19'th Dec 2023
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, e
Buy These 4 Low-Beta Stocks to Counter Market Volatility
09:46am, Friday, 15'th Dec 2023
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
New Strong Buy Stocks for December 13th
07:32am, Wednesday, 13'th Dec 2023
TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript
09:14am, Sunday, 05'th Nov 2023
Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston -
Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript
04:30pm, Friday, 04'th Aug 2023
Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CF
Galapagos Stands Strong On Jyseleca Positive Clinical Data
01:59am, Saturday, 06'th May 2023
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T ther
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
10:35am, Friday, 24'th Feb 2023
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
07:07am, Saturday, 11'th Feb 2023
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the st
